Prognostic Factors for Clinical Response in Systemic Lupus Erythematosus Patients Treated by Allogeneic Mesenchymal Stem Cells
Systemic lupus erythematosus (SLE) is an autoimmune disease with a broad range of clinical manifestations and a heterogeneous disease course. There is no cure for SLE, but current standard pharmacotherapies can improve disease prognosis in most patients. However, some patients are refractory to conv...
Saved in:
Main Authors: | Lihui Wen (Author), Myriam Labopin (Author), Manuela Badoglio (Author), Dandan Wang (Author), Lingyun Sun (Author), Dominique Farge-Bancel (Author) |
---|---|
Format: | Book |
Published: |
Hindawi Limited,
2019-01-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Umbilical Cord-Derived Mesenchymal Stem Cells Suppress Autophagy of T Cells in Patients with Systemic Lupus Erythematosus via Transfer of Mitochondria
by: Jinyun Chen, et al.
Published: (2016) -
Clinical Efficacy and Safety of Mesenchymal Stem Cells for Systemic Lupus Erythematosus
by: Tianbiao Zhou, et al.
Published: (2020) -
An Update for Mesenchymal Stem Cell Therapy in Lupus Nephritis
by: Wenchao Li, et al.
Published: (2021) -
In Vivo Immunogenic Response to Allogeneic Mesenchymal Stem Cells and the Role of Preactivated Mesenchymal Stem Cells Cotransplanted with Allogeneic Islets
by: Régis Linhares Oliveira, et al.
Published: (2017) -
Mesenchymal stem cells avoid allogeneic rejection
by: Murphy J Mary, et al.
Published: (2005)